New: Blinatumomab Resources
Blinatumomab is standard of care for children with relapsed acute lymphoblastic leukemia (ALL) and in de novo pediatric ALL for those who cannot tolerate or are resistant to conventional chemotherapy.
Advanced centres are able to provide blinatumomab as of fall 2024.
